Australia's largest stock trading and investment forum Australia's #1 stock forum

ACR

0.00%

5.4¢ acrux limited

also what strength 5% or the 7.5% Jet

First 25 Last

Share
Profile

Follow
jetrodder

6,036 Posts.

50

05/04/24

13:29

Post #: 73206958
Share

Originally posted by Hadrian: ↑

The launch of Dapsone in the US caught my attention. I hold stock in Mayne Pharma which has marketed this drug in the US since late 2021 and has over 30% market share (mainly distributing for Encube and Cosette) and makes very little profit (if any) for Mayne Pharma. Marketing generics in the US is a cut throat business, particularly when there's already 4 or 5 other players in the market as is the case here. The only players which make a profit are wholesalers and PBMs (pharmaceutical benefits managers). Mayne Pharma distributes this product for others in the US through its own online pharmacy, over 40 sales team and network of dermatologist prescribers by passing wholesalers and PBMs and still struggles to be profitable. I can't see how a small player like ACR and its distributing partner, now entering this market will even get a look in. I can't see this product being a money earner for ACR and I hope for holders that the pipeline of products are more innovative than Dapsone. Good luck.

Expand

also what strength 5% or the 7.5% Jet

ACR Price at posting: 6.7¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

There are more pages in this discussion • 20 more messages in this thread...

First 25 Last

Add ACR (ASX) to my watchlist

(20min delay)
Last 5.4¢		Change 0.000(0.00%)		Mkt cap ! $15.69M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	434	5.4¢

Sellers (Offers)

Price($)	Vol.	No.
5.8¢	17258	1

View Market Depth

No.	Vol.	Price($)
1	434	0.054
2	16865	0.053
2	293669	0.052
3	119539	0.051
2	217490	0.050

Price($)	Vol.	No.
0.058	17258	1
0.059	18000	1
0.060	670	1
0.061	100000	1
0.062	116100	2

Last trade - 16.12pm 04/10/2024 (20 minute delay)

ACR (ASX) Chart

Day chart unavailable

also what strength 5% or the 7.5% Jet

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

also what strength 5% or the 7.5% Jet

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News